Life Science and Medical News from Around the Globe
Scientists Publish Blueprint to Apply Artificial Intelligence (AI) to Extend Human Longevity
On January 27, 2021, Deep Longevity, a fully-owned subsidiary of Regent Pacific (HKEX: 0575), specializing in the development and the application of next-generation artificial intelligence (AI) for aging and longevity research, announced the January 14, 2021 online publication of an open-access article in Nature Aging titled "Artificial Intelligence in Longevity Medicine” (https://www.nature.com/articles/s43587-020-00020-4). In the article, the authors describe a new field of study converging AI, basic research, and medicine referred to as Longevity Medicine. Another definition for Longevity Medicine is the preventative and restorative medicine enabled by the deep-aging clocks and artificial intelligence. The article was authored by Alex Zhavoronkov, PhD, the Founder and Chief Longevity Officer of Deep Longevity, a computer scientist with a doctoral degree in biophysics; Evelyne Yehudit Bischof, MD, MPH, a practicing medical doctor trained in the top European and the US medical schools actively engaged in aging research and gero-oncology at the University Hospital Basel in Switzerland, and at Shanghai University of Medicine and Health Sciences; and Kai-Fu Lee, PhD, one of the most prolific scientists and entrepreneurs in artificial intelligence, and Chairman and CEO of Sinovation Ventures (https://www.sinovationventures.com/). The traditional approach to medicine is to treat diseases. However, scientists estimate (Cutler and Mattson, 2006) that complete elimination of cancer would result in only a 2.3-year increase in life expectancy in the US at birth and 1.3-year gain at age 65. Complete elimination of influenza and pneumonia would yield gains of 0.5 years and 0.2 years in life expectancy in general.